OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The firm is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.